Kak dobit'sya bolee effektivnogo kontrolya bronkhial'noy astmy s pomoshch'yu novogo podkhoda k naznacheniyu lekarstvennykh sredstv? Preimushchestvo gibkogo dozirovaniya


Cite item

Full Text

Abstract

Бронхиальная астма (БА) является хроническим воспалительным заболеванием дыхательных путей, в котором играют роль многие клетки и клеточные элементы. Хроническое воспаление вызывает сопутствующее повышение гиперреактивности дыхательных путей, приводящее к повторяющимся эпизодам свистящих хрипов, одышки, чувства стеснения в груди и кашля, особенно ночью или ранним утром [1, 2]. В настоящее время общепризнано, что ингаляционные глюкокортикостероиды (ИГКС) являются наиболее эффективными противовоспалительными препаратами для терапии БА. С пониманием центральной роли воспалительного процесса в генезе БА изменились подходы к назначению ИГКС: они рекомендованы как препараты первой линии практически для всех больных БА, в том числе и с легкой степенью БА

About the authors

S. N Avdeev

НИИ пульмонологии МЗ и СР РФ, Москва

References

  1. GINA, Global Strategy for Asthma Management and Prevention. NHI Publication No.02-3659. 2002. www.ginasthma.com
  2. British Thoracic Society and Scottish Intercollegiate Guidelines Network Guidelines on Asthma. Thorax 2003; 58 (Suppl. I): i1–i94.
  3. Barnes P.J, Adcock I.M. Anti - inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436–41.
  4. Barnes P.J, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157: S1–S53.
  5. Suissa S, Ernst P, Benayoun S et al. Low - dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–6.
  6. Shrewsbury S, Pyke S, Britton M. Meta - analysis of increased dose of inhaled steroid or addiction of salmeterol in symptomatic asthma (MIASMA). Brit Med J 2000; 320: 1368–73.
  7. Pauwels R.A, Lofdahl C.G, Postma D.S et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11.
  8. O’Byrne P.M, Barnes P.J, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392–7.
  9. Barnes P.J. Clinical outcome of adding long - acting beta - agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–16.
  10. Roth M, Rudiger J.J, Bihl M.P et al. The b2-agonist formoterol activates the glucocorticoid receptor in vivo. Eur Respir J 2000; 18 (Suppl. 31): 437s–438s.
  11. Barnes P.J. Scientific rationale for inhaled combination therapy with long - acting beta - agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
  12. Reddel H.K, Jenkins C.R, Marks G.B et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226–35.
  13. Rabe K.F, Vermeire P.A, Soriano J.B, Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–7.
  14. Bateman E.D, Boushey H.A, Bousquet J et al. for the GOAL Investigators Group. Can Guideline - defined Asthma Control Be Achieved?: The Gaining Optimal Asthma controL Study. Am J Respir Crit Care Med 2004; 170: 836–44.
  15. Haantela T. The disease management approach to controlling asthma. Respir Med 2002; 96 (Suppl. A): S1–S8.
  16. Kuna P, Kuprys I. Symbicort Turbuhaler: a new concept in asthma management. Int J Clin Pract 2002; 56: 797–803.
  17. Kips J.C, O'Connor B.J, Inman M.D et al. A long - term study of the antiinflammatory effect of low - dose budesonide plus formoterol versus high - dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996–1001.
  18. Foresi A, Morelli M.C, Catena E. Low - dose budesonide with the addition of an increased dose during exacerbations is effective in long - term asthma control, On behalf of the Italian Study Group. Chest 2000; 117: 440–6.
  19. Lahdensuo A, Haahtela T, Herrala J et al. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 1998; 316: 1138–9.
  20. Gibson P.G, Powell H, Coughlan J et al. Self - management education and regular practitioner review for adults with asthma (Cochrane Review). In: The Cochrane Library, Issue 1, 2005. Oxford: Update Software.
  21. Haughney J, Barnes G, Partridge M. Living and breathing – а national survey of patients views of asthma and its treatment. Thorax 2001; Suppl III: iii17 (S51).
  22. Palmqvist M, Persson G, Lazer L et al. Inhaled dry - power formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2482–9.
  23. Engel T, Dirksen A, Heinig J.H et al. Single - dose inhaled budesonide in subjects with chronic asthma. Allergy 1991; 46: 547–53.
  24. Gibson P.G, Saltos N, Fakes K. Acute anti - inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med 2001; 163: 32–6.
  25. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003; 16: 147–51.
  26. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244–9.
  27. Aalbers R, Backer V, Kava T.T et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed - dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225–40.
  28. Цой А.Н., Архипов В.В. Комбинированная терапия бронхиальной астмы: перспективы гибкого дозирования. Consilium medicum 2004; 6: 751–4.
  29. Stallberg B, Olsson P, Jorgensen L.A et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57: 656–61.
  30. Fitz Gerald J.M, Sears M.R, Boulet L.P et al. Canadian Investigators. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five - month multicentre Canadian study. Can Respir J 2003; 10: 427–34.
  31. Mitchils A. Adjustable maintenance dosing with budesonide/formoterol in asthma patients. Allergy Clin Immunol Int 2003; 15(Suppl. 1) (poster 239).
  32. Buhl R, Kardos P, Richter K et al. The effect of adjustable dosing with budesonide/formoterol on health - related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin 2004; 20: 1209–20.
  33. Moretti A.M, Canonica G.W, Sanguinetti C.M et al. Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study. Eur Respir J 2003; 22 (Suppl. 45): 259s [P1703].
  34. Leuppi J.D, Salzberg M, Meyer L et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly 2003; 133: 302–9.
  35. Ind P.W, Haughney J, Price D et al. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004; 98: 464–75.

Copyright (c) 2005 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies